READ-ONLY DIGITIZATION RESULT
Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial.
Nat Commun · 2026-Mar-14 · PMID 41826281
Panel A质量警告待 EXE 对齐验证
Progression-free Survival
Fig. 2. Progression-free survival by bevacizumab use. Kaplan–Meier estimate in subgroups with bevacizumab use ( A ) and without bevacizumab use ( B ), and subgroup analysis ( C ). Source data are provided as a Source data file.
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
| Curve | 序号 | X (norm) | Y (norm) | X (real) | Y (real) | X (pixel) | Y (pixel) |
|---|---|---|---|---|---|---|---|
| 1 | 1 | 0.0000 | 0.9949 | 0.0000 | 99.4872 | 136 | 14 |
| 1 | 2 | 0.0154 | 0.9897 | 0.5560 | 98.9744 | 144 | 15 |
| 1 | 3 | 0.0174 | 0.9897 | 0.6255 | 98.9744 | 145 | 15 |
| 1 | 4 | 0.0193 | 0.9897 | 0.6950 | 98.9744 | 146 | 15 |
| 1 | 5 | 0.0212 | 0.9897 | 0.7645 | 98.9744 | 147 | 15 |
| 1 | 6 | 0.0232 | 0.9846 | 0.8340 | 98.4615 | 148 | 16 |
| 1 | 7 | 0.0251 | 0.9846 | 0.9035 | 98.4615 | 149 | 16 |
| 1 | 8 | 0.0270 | 0.9846 | 0.9730 | 98.4615 | 150 | 16 |
| 1 | 9 | 0.0290 | 0.9846 | 1.0425 | 98.4615 | 151 | 16 |
| 1 | 10 | 0.0309 | 0.9846 | 1.1120 | 98.4615 | 152 | 16 |
| 1 | 11 | 0.0328 | 0.9846 | 1.1815 | 98.4615 | 153 | 16 |
| 1 | 12 | 0.0347 | 0.9846 | 1.2510 | 98.4615 | 154 | 16 |
| 1 | 13 | 0.0367 | 0.9846 | 1.3205 | 98.4615 | 155 | 16 |
| 1 | 14 | 0.0386 | 0.9846 | 1.3900 | 98.4615 | 156 | 16 |
| 1 | 15 | 0.0405 | 0.9846 | 1.4595 | 98.4615 | 157 | 16 |
| 1 | 16 | 0.0425 | 0.9846 | 1.5290 | 98.4615 | 158 | 16 |
| 1 | 17 | 0.0444 | 0.9846 | 1.5985 | 98.4615 | 159 | 16 |
| 1 | 18 | 0.0463 | 0.9846 | 1.6680 | 98.4615 | 160 | 16 |
| 1 | 19 | 0.0483 | 0.9846 | 1.7375 | 98.4615 | 161 | 16 |
| 1 | 20 | 0.0502 | 0.9846 | 1.8069 | 98.4615 | 162 | 16 |
| 1 | 21 | 0.0521 | 0.9846 | 1.8764 | 98.4615 | 163 | 16 |
| 1 | 22 | 0.0541 | 0.9846 | 1.9459 | 98.4615 | 164 | 16 |
| 1 | 23 | 0.0560 | 0.9846 | 2.0154 | 98.4615 | 165 | 16 |
| 1 | 24 | 0.0579 | 0.9846 | 2.0849 | 98.4615 | 166 | 16 |
| 1 | 25 | 0.0598 | 0.9846 | 2.1544 | 98.4615 | 167 | 16 |
| 1 | 26 | 0.0618 | 0.9846 | 2.2239 | 98.4615 | 168 | 16 |
| 1 | 27 | 0.0637 | 0.9846 | 2.2934 | 98.4615 | 169 | 16 |
| 1 | 28 | 0.0656 | 0.9846 | 2.3629 | 98.4615 | 170 | 16 |
| 1 | 29 | 0.0676 | 0.9846 | 2.4324 | 98.4615 | 171 | 16 |
| 1 | 30 | 0.0695 | 0.9744 | 2.5019 | 97.4359 | 172 | 18 |
| 1 | 31 | 0.0714 | 0.9744 | 2.5714 | 97.4359 | 173 | 18 |
| 1 | 32 | 0.0734 | 0.9744 | 2.6409 | 97.4359 | 174 | 18 |
| 1 | 33 | 0.0753 | 0.9744 | 2.7104 | 97.4359 | 175 | 18 |
| 1 | 34 | 0.0772 | 0.9744 | 2.7799 | 97.4359 | 176 | 18 |
| 1 | 35 | 0.0792 | 0.9795 | 2.8494 | 97.9487 | 177 | 17 |
| 1 | 36 | 0.0811 | 0.9846 | 2.9189 | 98.4615 | 178 | 16 |
| 1 | 37 | 0.0830 | 0.9846 | 2.9884 | 98.4615 | 179 | 16 |
| 1 | 38 | 0.0849 | 0.9846 | 3.0579 | 98.4615 | 180 | 16 |
| 1 | 39 | 0.0869 | 0.9846 | 3.1274 | 98.4615 | 181 | 16 |
| 1 | 40 | 0.0888 | 0.9846 | 3.1969 | 98.4615 | 182 | 16 |
| 1 | 41 | 0.0907 | 0.9692 | 3.2664 | 96.9231 | 183 | 19 |
| 1 | 42 | 0.0927 | 0.9692 | 3.3359 | 96.9231 | 184 | 19 |
| 1 | 43 | 0.0946 | 0.9692 | 3.4054 | 96.9231 | 185 | 19 |
| 1 | 44 | 0.0965 | 0.9692 | 3.4749 | 96.9231 | 186 | 19 |
| 1 | 45 | 0.0985 | 0.9692 | 3.5444 | 96.9231 | 187 | 19 |
| 1 | 46 | 0.1004 | 0.9692 | 3.6139 | 96.9231 | 188 | 19 |
| 1 | 47 | 0.1023 | 0.9692 | 3.6834 | 96.9231 | 189 | 19 |
| 1 | 48 | 0.1042 | 0.9692 | 3.7529 | 96.9231 | 190 | 19 |
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | quality_warning | 待验证 | 1 | 2026-07-23T16:50:35+00:00 |